US FDA approves Teva's Ajovy for migraine prevention in children

This is the first time a drug has been approved for preventing migraines in children.

The logo of Teva Pharmaceutical Industries is displayed at the company headquarters in Tel Aviv, Israel, February 20, 2024. / REUTERS/Dylan Martinez/File Photo

The U.S. Food and Drug Administration on Aug.5 approved Ajovy, an injection made by Israeli drugmaker Teva Pharma, to help prevent migraines in children aged six and older who weigh 45 kilograms or more.

This is the first time a drug has been approved for preventing migraines in children.

The injection is given once a month. The most common side effects are pain and redness where the shot is given.

Serious side effects include itchiness, rash and drug hypersensitivity, but the overall safety was similar to what was seen in adult migraine studies, the FDA said.

Episodic migraine refers to recurring severe headaches in children that do not occur daily but are frequent enough to interfere with daily activities.

These headaches are often accompanied by symptoms such as nausea, fatigue and sensitivity to light and sound.

Ajovy is part of a class of drugs called CGRP inhibitors, which block a protein involved in triggering migraines.

The treatment was first approved for adults in 2018 and competes with similar drugs such as Amgen's Aimovig and Eli Lilly's Emgality.

Comments

This is a Premium Article, available exclusively to our subscribers.

Read 500+ such News or articles every month by subscribing today!
Monthly

Free

Limited Access

Limited View

Free weekly E-Paper

Subscribe Now
Monthly

$10

Full Access

Unlimited View

Free weekly E-Paper

Free daily newsletter

Subscribe Now
Annual

$50

Full Access

Unlimited View

Free weekly E-Paper

Free daily newsletter

Subscribe Now
Start the conversation

Become a member of New India Abroad to start commenting.

Sign Up Now

Already have an account? Login